Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR): a National Multi-center, Retrospective-prospective, Cohort Study Initiated by the Investigators
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 2,000
- Locations
- 1
- Primary Endpoint
- Change in the incidence of MACCE
Study Overview
Brief Summary
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Detailed Description
Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with clinically confirmed infective endocarditis
Exclusion Criteria
- •Patients refuse to sign informed consent form
- •Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Outcomes
Primary Outcomes
Change in the incidence of MACCE
Time Frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
Secondary Outcomes
- Change in the incidence of myocardial infarction(1, 3, 6 months and 1, 2, 3, 5 years after enrollment.)
- Incidence of adverse thrombus complications(5 years after the enrollment.)
- Change in the incidence of stroke(1, 3, 6 months and 1, 2, 3, 5 years after enrollment.)
- Change in the incidence of all-cause death(1, 3, 6 months and 1, 2, 3, 5 years after enrollment.)
- Change in the incidence of infection recurrence(1, 3, 6 months and 1, 2, 3, 5 years after enrollment.)
- Change in the incidence of vessel revascularization(1, 3, 6 months and 1, 2, 3, 5 years after enrollment.)